Quadrant Capital Group’s Nurix Therapeutics NRIX Stock Holding History

Quadrant Capital Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.33K	Buy	344 +278	+421%	+$4.61K	﹤0.01%	2338
2025 Q4	$1.25K	Hold	66	–	–	﹤0.01%	2577
2025 Q3	$610	Buy	+66	New	+$685	﹤0.01%	2594
2025 Q2	–	Sell	-66	Closed	-$785	–	2159
2025 Q1	$785	Hold	66	–	–	﹤0.01%	2608
2024 Q4	$1.24K	Hold	66	–	–	﹤0.01%	2562
2024 Q3	$1.48K	Hold	66	–	–	﹤0.01%	2538
2024 Q2	$1.38K	Hold	66	–	–	﹤0.01%	2527
2024 Q1	$971	Hold	66	–	–	﹤0.01%	2590
2023 Q4	$682	Sell	66 -49	-43%	-$336	﹤0.01%	2591
2023 Q3	$904	Sell	115 -1,367	-92%	-$12.5K	﹤0.01%	2498
2023 Q2	$14.8K	Hold	1,482	–	–	﹤0.01%	1859
2023 Q1	$13.2K	Buy	+1,482	New	+$15.4K	﹤0.01%	1903

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Quadrant Capital Group's NRIX Position: Q1 2026 in Review

Quadrant Capital Group increased its Nurix Therapeutics (NRIX) stake by 421% in Q1 2026, buying an estimated $4.61K and bringing the position to 344 shares worth $5.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2338.

Quadrant Capital Group first reported a position in NRIX in Q1 2023 and has held it in 12 quarters since. The position peaked at $14.8K in Q2 2023. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Quadrant Capital Group held 344 shares of Nurix Therapeutics worth $5.33K as of Q1 2026.
Quadrant Capital Group bought 278 Nurix Therapeutics shares in Q1 2026, an estimated $4.61K.
Nurix Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2338 holding.
Quadrant Capital Group first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 12 quarters since.
Quadrant Capital Group's Nurix Therapeutics position peaked at $14.8K in Q2 2023.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.